Value Based Consultant LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$5,380	1
2024	Research	$905	3
2023	Research	$37,845	21
2022	Research	$5,265	6
2021	Research	$52,846	22
2020	Research	$4,580	2

Breakdown

Who paid Research payments · program years 2020–2025

F. Hoffmann-La Roche AG $31,900 8 payments
Roche Products Limited $22,840 20 payments
BeiGene (Suzhou) Co., Ltd. $17,840 7 payments
BeiGene, Ltd. $13,400 17 payments
BeiGene AUS Pty Ltd $12,201 1 payment
AstraZeneca UK Limited $5,380 1 payment
BeiGene USA, Inc. $3,260 1 payment

Studies the money was for Research payments · program years 2020–2025

B Fast Blood First Assay Screening Trial Umbrella Study Bfast Blood First Assay Screening Trial $31,900 8 payments
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma $29,675 15 payments
Atezolizumab Versus Placebo As Adjuvant Therapy in Locally Advanced Head and Neck Cancer $22,840 20 payments
A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors $12,201 1 payment
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer $5,380 1 payment
Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer $3,905 7 payments
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer $865 2 payments
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer $55 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.